GGHC
ARRY

Gilder Gagnon Howe & Co’s Array Biopharma Inc ARRY Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,221,310
Closed -$29.8M – 306
2019
Q1 		$29.8M Buy
+1,221,310
New +$25.4M 0.32% 81

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gilder Gagnon Howe & Co's ARRY Position: Q2 2019 in Review

Gilder Gagnon Howe & Co sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 1,221,310 shares — an estimated $29.8M sold.

Gilder Gagnon Howe & Co first reported a position in ARRY in Q1 2019 and held it in 1 quarter. The position peaked at $29.8M in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Gilder Gagnon Howe & Co reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 1,221,310 Array Biopharma Inc shares in Q2 2019, an estimated $29.8M.
  • Gilder Gagnon Howe & Co first reported a position in Array Biopharma Inc in Q1 2019 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Array Biopharma Inc position peaked at $29.8M in Q1 2019.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2019, filed 13 Aug 2019.